Metadata record for the manuscript: On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer

Summary This metadata record provides details of the data supporting the claims of the related manuscript: “On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer”. The related study addressed how circulating tumor DNA (ctDNA) levels change during chemotherapy by serially monitoring ctDNA in patients with colorectal cancer during the 48-hour application of FOLFOX. Data access The sequencing raw data sets have been deposited at the European Genome-phenome Archive (EGA; http://www.ebi.ac.uk/ega/) under study accession number https://identifiers.org/ega.study:EGAS00001004213. This study contains the following four datasets: 1: sWGS of CRC patients (https://identifiers.org/ega.dataset:EGAD00001006101), 2: Mutation analysis data (AVENIO ctDNA Targeted Kit: https://identifiers.org/ega.dataset:EGAD00001006103, SiMSen-seq approach: https://identifiers.org/ega.dataset:EGAD00001006104, Deep sequencing: https://identifiers.org/ega.dataset:EGAD00001006105). Data access requests can be made to the appropriate Data Access Committee via the EGA landing page for each dataset. In addition to the sequencing data, the following data underlie the supplementary figures and tables of the related manuscript. Summary_file2.xlsx underlies Supplementary table 1 and Supplementary figures 8 and 10, and is available from the figshare repository at https://doi.org/10.6084/m9.figshare.13067348.v2. 41586_2019_1272_MOESM2_ESM.xlsx underlies Supplementary figure 11, and is available in the Supplementary Tables of Cristiano et al. (2019): https://doi.org/10.1038/s41586-019-1272-6. Name of Institutional Review Board or ethics committee that approved the study The study was approved by the Ethics Committee of the Medical University of Graz (approval number 26-288 ex 13/14 for the study part involving patients under FOLFOX treatment and 29-272 ex 16/17 for the collection and analysis of blood samples from healthy controls) conducted according to the Declaration of Helsinki. Written informed consent was obtained from all patients and healthy individuals, respectively.